NO20042001L - Additive cellebeskyttende effekter av to bioaktive omrader av pro-opiomelanokortinhormon - Google Patents

Additive cellebeskyttende effekter av to bioaktive omrader av pro-opiomelanokortinhormon

Info

Publication number
NO20042001L
NO20042001L NO20042001A NO20042001A NO20042001L NO 20042001 L NO20042001 L NO 20042001L NO 20042001 A NO20042001 A NO 20042001A NO 20042001 A NO20042001 A NO 20042001A NO 20042001 L NO20042001 L NO 20042001L
Authority
NO
Norway
Prior art keywords
komet
sequences
cell protective
yggfm
sysmehfrwgkpv
Prior art date
Application number
NO20042001A
Other languages
English (en)
Inventor
Zlatko Ademovic
Nikola Stambuk
Pasko Konjevoda
Darko Mikus
Original Assignee
Darko Mikus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darko Mikus filed Critical Darko Mikus
Publication of NO20042001L publication Critical patent/NO20042001L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Datamaskinanalyse ble anvendt for å definere gjentakende og bioaktive områder av proopiomelanokortin SYSMEHFRWGKPV og YGGFM. Cellebeskyttende modeller av etanolinduserte magelesjoner ble anvendt for å bevise de ytterligere cellebeskyttende effekter av kombinasjonen av sekvensene SYSMEHFRWGKPV og YGGFM, når de sammenliknes med de enkelte peptidsekvenser. Kombinasjoner av de to sekvensene SYSMEHFRWGKPV og YGGFM betegnet KOMET og er patentert. Hensikten med administrering av KOMET er å oppnå bedre og sterkere farmakologiske effekter på systemisk og lokal modulering av inflammasjon og sårheling. Ytterligere strukturformler som representerer ulike kombinasjoner av begge sekvenser ble også definert som KOMET-1 med sekvensen YGGFMSYSMEHFRWGKPVYGGFM, KOMET-2 med sekvensen YGGFMSYSMEHFRWGKPV og KOMET-3 med sekvensen SYSMEHFRWGKPVYGGFM.
NO20042001A 2001-10-18 2004-05-14 Additive cellebeskyttende effekter av to bioaktive omrader av pro-opiomelanokortinhormon NO20042001L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BA010898 2001-10-18
PCT/BA2001/000005 WO2003033017A1 (en) 2001-10-18 2001-11-29 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone

Publications (1)

Publication Number Publication Date
NO20042001L true NO20042001L (no) 2004-05-14

Family

ID=3839672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042001A NO20042001L (no) 2001-10-18 2004-05-14 Additive cellebeskyttende effekter av to bioaktive omrader av pro-opiomelanokortinhormon

Country Status (15)

Country Link
US (1) US7544653B2 (no)
EP (1) EP1435999B1 (no)
JP (1) JP2005508356A (no)
CN (1) CN1321687C (no)
AU (1) AU2002240733B2 (no)
BR (1) BR0117155A (no)
CA (1) CA2462713C (no)
CY (1) CY1114016T1 (no)
DK (1) DK1435999T3 (no)
ES (1) ES2391551T3 (no)
MX (1) MXPA04003504A (no)
NO (1) NO20042001L (no)
PT (1) PT1435999E (no)
RU (1) RU2297238C2 (no)
WO (1) WO2003033017A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2857588B1 (fr) * 2003-07-17 2007-11-30 Oreal Utilisation de beta-endorphine, d'agents exercant une activite beta-endorphine-like en cosmetique et dermatologie
AU2011265315B2 (en) * 2004-05-12 2014-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
WO2010054446A1 (en) 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
WO2015033175A1 (en) 2013-09-06 2015-03-12 Zlatko Ademovic Combination of pro-opiomelanocortin endogenous peptides in autoimmune disease treatment
US10644009B2 (en) 2017-12-21 2020-05-05 Renesas Electronics Corporation Semiconductor memory device
CN109824772B (zh) * 2019-02-28 2022-07-29 海南大学 一组提高血清糖皮质激素水平的基因重组人促皮质素前体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864250B1 (en) * 1997-08-22 2005-03-08 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
AU5055799A (en) * 1998-07-22 2000-02-14 Smith & Nephew Plc Dermatological compositions for the treatment of scars
AU765753B2 (en) * 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Also Published As

Publication number Publication date
JP2005508356A (ja) 2005-03-31
ES2391551T3 (es) 2012-11-27
CY1114016T1 (el) 2016-07-27
PT1435999E (pt) 2012-10-24
RU2297238C2 (ru) 2007-04-20
EP1435999A1 (en) 2004-07-14
US20050014696A1 (en) 2005-01-20
AU2002240733B2 (en) 2009-04-09
CA2462713A1 (en) 2003-04-24
RU2004114992A (ru) 2005-04-20
CA2462713C (en) 2014-03-18
DK1435999T3 (da) 2012-10-22
CN1558772A (zh) 2004-12-29
BR0117155A (pt) 2004-10-26
MXPA04003504A (es) 2005-06-20
CN1321687C (zh) 2007-06-20
EP1435999B1 (en) 2012-07-18
WO2003033017A1 (en) 2003-04-24
US7544653B2 (en) 2009-06-09

Similar Documents

Publication Publication Date Title
JPS5267532A (en) Semiconductor memory unit
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
AU8165982A (en) 4-aminosalicylic acid as an anti-inflammatory agent
NO20042001L (no) Additive cellebeskyttende effekter av to bioaktive omrader av pro-opiomelanokortinhormon
NO20031648D0 (no) Farmasöytiske lösninger av modafinilforbindelser
ITTO920303A1 (it) Composizione farmaceutica antiinfiammatoria
ATE275143T1 (de) Verbindungen
SE429857B (sv) Polyaminoeter till anvendning vid tillverkning av tillsatser for smorjoljor
DK1131356T3 (da) Monoklonalt alfa-D (ITGAD)-antistof til anvendelse i behandlingen af CNS-læsioner foranlediget af trauma
ES2162678T3 (es) Nuevos derivados diarilmetilideno furanicos, sus procedimientos de preparacion y sus utilizaciones en terapeutica.
RO72151A (ro) Explozivi sub forma de gel spumati,stabilizati
UY25818A (es) Modificacion cristalina b del acido 8-ciano-1-ciclopropil-7- (1s,6s-2,8-diazabiciclo[4.3.0]-nonan-8-il)-6-fluor-1,4-dihidro-4-oxo-3-quinolincarboxilico
DK1137640T3 (da) Cykliske hydrazinderivater som TNF-alfa-inhibitorer
DK1007052T3 (da) Kombinationer af endometrisk skånende progesteroner og endometrisk atrofiserende progesteroner med östrogener ved oral svangerskabs-forebyggelse
AR030241A1 (es) Compuestos derivados de tienopirrolidinona, su uso, medicamentos que los contienen, un procedimiento para preparar dichos compuestos y compuestos intermediarios
GB556351A (en) Improvements in pipe insulation sections for outside use
FR2429251A1 (fr) Nouvelle composition de matiere, articles formes a partir de celle-ci et leurs applications, notamment a titre de joints a ostomies
JPS5250659A (en) Timing output generation circuit
JPS5296843A (en) Phase adjuster
JPS52112800A (en) Electrical insulation composition
UA37942A (uk) Дуоденальний зонд
XU et al. The role of WeChat public platform in autonomic learning of medical students
UA34186A (uk) Спосіб лікування запалення, що виникає при поєднаних доброякісних процесах матки
JPS5379892A (en) Preparation of 7alpha-methoxy cephalospolin derivatives
JPS5284868A (en) Lighting circuit for dual discharge lamps

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application